ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in those patients without…

Continue Reading

News Source: medicalxpress.com